As GLP-1 receptor agonists such as semaglutide gain global attention, GLP-1 has evolved from a medical term into one of the most talked-about opportunities in the dietary supplement and functional food industries.
As SupplySide Global 2026 approaches, the global health and nutrition industry is turning its attention to Las Vegas. With growing interest in metabolic health and weight management, consumers and brands are exploring more convenient, non-injectable approaches to wellness. Probiotic technology is emerging as an innovative area of research in the evolving GLP-1 market.
01 | The GLP-1 Wave: From Drug Injections to Natural Gut-Based Regulation
GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone that plays important roles in glucose metabolism, appetite regulation, satiety, and gastric emptying. Secreted by intestinal L cells, it acts as one of the body's natural satiety signals.
While GLP-1 receptor agonists have transformed metabolic care, they can involve significant costs, injectable administration for many formulations, potential gastrointestinal side effects, and weight regain after treatment discontinuation. These factors are driving interest in complementary approaches and new product concepts across the global functional food and dietary supplement industries.
One promising research direction is supporting the body's own GLP-1 secretion through the gut microbiome.
By exploring specific probiotic strains that interact with the intestinal environment and enteroendocrine L cells, researchers are investigating new ways to influence endogenous GLP-1 secretion. This approach aligns with growing interest in microbiome-focused wellness and offers ingredient developers new opportunities for metabolic health formulations.
In simple terms: rather than introducing a hormone through medication, researchers are exploring ways to encourage the body to produce more of its own.
02 | A Science-Driven Innovation: UNISONS® GLP1-LP
Ahead of SupplySide Global 2026, UNISONS® (Yansheng Biology) is showcasing an innovative probiotic strain: Lactiplantibacillus plantarum GLP1-LP, designed to explore new possibilities in metabolic health ingredient development.
Chinese Invention Patent Granted
“A Strain of Lactobacillus plantarum Capable of Promoting Glucagon-Like Peptide-1 (GLP-1) Secretion”
Targeted Mechanism: From GPR120 to GLP-1
Research indicates that GLP1-LP can activate the fatty acid receptor GPR120 and promote endogenous GLP-1 secretion.
GPR120 is an important fatty acid-sensing receptor expressed in enteroendocrine cells. Its activation can trigger GLP-1 release from intestinal L cells, making it a promising target for research into appetite and metabolic regulation.
Increased GLP-1 Levels in In Vitro Testing
In vitro experimental data show that the culture supernatant of GLP1-LP significantly increased GLP-1 levels, with a concentration-dependent response: higher supernatant concentrations produced greater effects on GLP-1 secretion.
These findings support further investigation into the strain's potential applications in metabolic health.
Three Areas of Metabolic Research: From Appetite to Weight Management
1. Appetite Regulation and Gastric Emptying
GLP-1 plays a role in satiety and gastric emptying. GLP1-LP is being investigated for its potential to support these pathways through endogenous GLP-1 secretion.
2. Glucose Metabolism
In animal studies, GLP1-LP was reported to reduce fasting blood glucose (FBG), moderate postprandial glucose fluctuations, and improve metabolic markers associated with type 2 diabetes.
3. Weight Management and Lipid Metabolism
Animal studies reported reduced weight gain and improvements in serum lipid markers, including total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C).
These preclinical findings offer a foundation for further research and formulation development. Human clinical studies would be needed to establish corresponding benefits in people.
High Viable Cell Counts × Excellent Stability: Designed for Commercial Applications
A promising mechanism is only part of the equation. For ingredient innovation to succeed commercially, stability and manufacturing performance matter, too.
GLP1-LP is designed to combine high viable cell counts with strong shelf-life stability, supporting exploration across a range of delivery formats, including:
Powdered drink mixes
Capsules
Gummies
For brands developing next-generation metabolic health products, processing compatibility and stability during ambient storage are important considerations in ingredient selection and product development.
03 | Meet Us in Las Vegas: Discover New Possibilities in Microbiome Innovation
As a leading global event for dietary supplements, functional foods, and beverage innovation, SupplySide Global 2026 brings together forward-thinking ingredient suppliers, manufacturers, and brands from around the world.
At this year's show, UNISONS® will introduce its innovative L. plantarum GLP1-LP strain alongside a broader portfolio of proprietary probiotic strains and formulation solutions.
Whether you're developing products for metabolic health, weight management, gut health, women's health, or other emerging wellness categories, our team is ready to explore potential ingredient and OEM/ODM collaboration opportunities with you.
Looking for your next differentiated probiotic ingredient? Let's connect and explore what's possible.
#SupplySideGlobal #GLP1 #MetabolicHealth #WeightManagement #Probiotics #Microbiome #IngredientInnovation #DietarySupplements #FunctionalFoods #UNISONS
